MW 463.6 Da, Purity >98%. Novel, selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. Binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, thus resulting in the inhibition of tumor cell proliferation and tumor cell death.
Images
Publications
Filter by
- Hepatology communications 6:1574-15882022FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2 Mouse Model of Primary Sclerosing Cholangitis.Applications:Unspecified applicationReactive species:Unspecified reactive speciesApril O'Brien,Tianhao Zhou,Tori White,Abigail Medford,Lixian Chen,Konstantina Kyritsi,Nan Wu,Jonathan Childs,Danaleigh Stiles,Ludovica Ceci,Sanjukta Chakraborty,Burcin Ekser,Leonardo Baiocchi,Guido Carpino,Eugenio Gaudio,Chaodong Wu,Lindsey Kennedy,Heather Francis,Gianfranco Alpini,Shannon GlaserPubMed 35271760
- International journal of molecular medicine 36:442-82015Recruitment of mesenchymal stem cells by stromal cell-derived factor 1α in pulp cells from deciduous teeth.Applications:Unspecified applicationReactive species:Unspecified reactive speciesYuki Akazawa,Tomokazu Hasegawa,Yoshitaka Yoshimura,Naoyuki Chosa,Takeyoshi Asakawa,Kimiko Ueda,Asuna Sugimoto,Takamasa Kitamura,Hiroshi Nakagawa,Akira Ishisaki,Tsutomu IwamotoPubMed 26082290
Key facts
- CAS number
- 1035270-39-3
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 463.6 Da
- Molecular formula
- C26H33N5O3
- PubChem identifier
- 51039095
- Nature
- Synthetic
Target data
Alternative names
ACH, BBDS, BEK, BEK fibroblast growth factor receptor, BFGFR, BFR1, Basic fibroblast growth factor receptor 1, CD 333, CD 334, CD309, CD309 antigen, CD331, CD332, CD332 antigen, CD333 antigen, CD334 antigen, CEK, CEK 2, CEK3, CFD1, Craniofacial dysostosis 1, EC 2.7.10.1, ECT1, FGF receptor, FGFBR, FGFR1/PLAG1 fusion, FGFR1_HUMAN, FGFR2_HUMAN, FGFR3_HUMAN, FGFR4_HUMAN, FLG, FLK-1, FLK1, mouse, homolog of, FLT-2, Fetal liver kinase 1, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 3, Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism), Fibroblast growth factor receptor 4, Fms-like gene, Fms-like tyrosine kinase 2, HBGFR, HH2, HRTFDS, HSFGFR3EX, JTK 2, JTK 4, JWS, Jackson Weiss syndrome, K-sam, KAL2, KGFR, KRD1, Kdr, Keratinocyte growth factor receptor, Keratinocyte growth factor receptor 2, Kinase insert domain receptor, Kinase insert domain receptor (a type III receptor tyrosine kinase), Ly73, MFR 3, MGC20292, N-SAM, OGD, Protein tyrosine kinase, Protein-tyrosine kinase receptor flk-1, Proto-oncogene c-Fgr, SAM 3, TK14, TK25, TKF, Tyrosine kinase JTK 4, Tyrosine kinase growth factor receptor, Tyrosine kinase related to fibroblast growth factor receptor, Tyrosylprotein kinase, VEGFR, VEGFR-2, VGFR2_HUMAN, Vascular endothelial growth factor receptor 2, Z FGFR 3, bFGF-R-1, bacteria-expressed kinase, fc13h 10, fibroblast growth factor receptor 1, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, protein tyrosine kinase, receptor like 14, soluble FGFR4 variant 4, soluble VEGFR2
Recommended products
MW 463.6 Da, Purity >98%. Novel, selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. Binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, thus resulting in the inhibition of tumor cell proliferation and tumor cell death.
Key facts
- CAS number
- 1035270-39-3
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 463.6 Da
- Molecular formula
- C26H33N5O3
- PubChem identifier
- 51039095
- Nature
- Synthetic
- Solubility
DMSO (>80 mg/ml).
- Biochemical name
- Azd-4547
- Biological description
Novel, selective inhibitor of the FGFR1, 2, and 3 tyrosine kinases. Binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, thus resulting in the inhibition of tumor cell proliferation and tumor cell death.
- Canonical SMILES
- CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC
- Isomeric SMILES
- C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC
- InChI
- InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
- InChIKey
- VRQMAABPASPXMW-HDICACEKSA-N
- IUPAC name
- N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
- Storage information
- Store in the dark, Store under desiccating conditions
Notes
This product is manufactured by BioVision, an Abcam company and was previously called 9403 AZD-4547. 9403-25 is the same size as the 25 mg size of ab216311.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
VEGF Receptor 2 also known as KDR or Flk-1 along with FGFR1 FGFR2 FGFR3 and FGFR4 are important targets in cellular signaling pathways. VEGFR2 with a molecular weight of approximately 150 kDa is a tyrosine kinase receptor prominently expressed in vascular endothelial cells. FGFRs share similar functional motifs and are expressed widely with variations in expression in tissue types like mesenchyme and oligodendrocytes. AZD-4547 is known as an FGFR inhibitor specifically targeting these receptors.
- Biological function summary
VEGFR2 and FGFRs play roles in angiogenesis and tissue development. VEGFR2 mediates endothelial cell proliferation migration and new blood vessel formation. FGFRs form a complex with fibroblast growth factors and mediate signaling that controls cell differentiation proliferation and survival. Both VEGFR2 and FGFRs interact in ligand-receptor complexes to induce downstream signaling cascades for tissue vascular and development processes.
- Pathways
VEGFR2 and FGFRs are integral to the MAPK and PI3K-Akt pathways. These pathways affect cellular responses such as growth and survival. VEGFR2's signaling interplays with proteins like PLCγ and Src to promote angiogenesis. FGFRs interact within the FGF signaling pathway connecting with proteins like SOS and Ras which regulate gene expression related to cell growth and differentiation.
- Associated diseases and disorders
VEGFR2 and FGFRs link to cancer and developmental syndromes. VEGFR2 is associated with pathological angiogenesis in various cancers and its overexpression can lead to tumor growth. Mutations in FGFRs cause disorders like skeletal dysplasia. Both VEGFR2 and FGFRs connect with other proteins such as PDGFR and EGFR influencing disease progression through altered signaling.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - AZD4547, FGFR inhibitor (ab216311)
2D chemical structure image of ab216311, AZD4547, FGFR inhibitor
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com